Keyline Bio ยท NewsPress releases, lab updates and events from Keyline Bio. Keyline Bio is a fictional company. Sample website by Xiobo Creative.https://keyline.xiobocreative.comen-usTalk at a protein design meeting in Boston (sample event)https://keyline.xiobocreative.com/news/protein-design-meeting-bostonhttps://keyline.xiobocreative.com/news/protein-design-meeting-bostonOur team shows one full loop, from design to lab result.Thu, 12 Nov 2026 00:00:00 GMTEventHow we design binders for flat protein surfaceshttps://keyline.xiobocreative.com/news/flat-surfaces-preprinthttps://keyline.xiobocreative.com/news/flat-surfaces-preprintA new preprint shows our approach for targets without a deep pocket.Tue, 06 Oct 2026 00:00:00 GMTNewsFirst patient dosed in the Phase 1 study of KL-101https://keyline.xiobocreative.com/news/first-patient-dosed-kl-101https://keyline.xiobocreative.com/news/first-patient-dosed-kl-101Keyline's first clinical study is open in recurrent or metastatic head and neck cancer.Tue, 15 Sep 2026 00:00:00 GMTPress releaseOur lab now screens 12,000 designs a weekhttps://keyline.xiobocreative.com/news/lab-doubleshttps://keyline.xiobocreative.com/news/lab-doublesA second robot line and a new binding assay double what we can test.Thu, 20 Aug 2026 00:00:00 GMTNewsKeyline raises $140M Series Bhttps://keyline.xiobocreative.com/news/series-bhttps://keyline.xiobocreative.com/news/series-bThe funding supports the Phase 1 study of KL-101 and grows the design and lab platform.Wed, 03 Jun 2026 00:00:00 GMTPress releaseIND for KL-101 now in effecthttps://keyline.xiobocreative.com/news/ind-clearance-kl-101https://keyline.xiobocreative.com/news/ind-clearance-kl-101Keyline can now start the first clinical study of a protein it designed.Wed, 18 Mar 2026 00:00:00 GMTPress releaseKeyline and Aldermoor start a partnership in autoimmune diseasehttps://keyline.xiobocreative.com/news/aldermoor-partnershiphttps://keyline.xiobocreative.com/news/aldermoor-partnershipKeyline will design binders for one target chosen by Aldermoor.Tue, 10 Feb 2026 00:00:00 GMTPress release